After reporting better than expected quarterly results and outlook, Cepheid shares soared about 22 percent on Friday, surpassing estimates on both counts.
Most of this is the result of increasing sales its GeneXpert DNA testing system. Profits in the second quarter grew to $0.03, beating analysts expectations of a loss of $0.02.
Cepheid (NASDAQ:CPHD) had its price target raised by Oppenheimer from $33.00 to $38.00. They have an “Outperform” rating on the company.
Jefferies (NYSE:JEF) raised its price target on Cepheid to $37.00. They have a “Buy” rating on the company.
Cepheid also had its price target increased by UBS AG (NYSE:UBS) from $32.00 to $35.00. They have a “Neutral” rating on the company.
Piper Jaffray (NYSE:PJC) raised its price target on Cepheid to $39.00.
Cepheid closed Friday at $40.77, gaining $9.14, or 28.90 percent.
No comments:
Post a Comment